{"product_id":"therapeutics-of-parkinsons-disease-and-other-movement-disorders-isbn-9780470066485","title":"Therapeutics of Parkinson's Disease and Other Movement Disorders","description":"\u003cul\u003e \u003cli\u003eProvides a comprehensive update on therapies for Parkinson’s disease and other movement disorders\u003c\/li\u003e \u003cli\u003eDescribes the basic mechanisms of neurodegeneration, pharmacologic interventions for motor and non-motor symptoms, and surgical management\u003c\/li\u003e \u003cli\u003eFeatures summary tables and algorithms that serve as a quick reference guide for practical treatment decisions\u003c\/li\u003e \u003cli\u003eThe expert guidance of recognised authorities will enable readers of this book to plan their patients’ care with greater confidence\u003cbr\u003e \u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003ePreface ix\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Parkinson’s Disease and Parkinsonism\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 The Etiopathogenesis of Parkinson’s Disease: Basic Mechanisms of Neurodegeneration 3\u003cbr\u003e \u003ci\u003eC. Warren Olanow and Kevin McNaught\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Physiology of Parkinson’s Disease 25\u003cbr\u003e \u003ci\u003eShlomo Elias, Zvi Israel and Hagai Bergman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Pharmacology of Parkinson’s Disease 37\u003cbr\u003e \u003ci\u003eJonathan M. Brotchie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 The Treatment of Early Parkinson’s Disease 49\u003cbr\u003e \u003ci\u003eOlivier Rascol and Regina Katzenschlager\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Treatment of Motor Complications in Advanced Parkinson’s Disease 71\u003cbr\u003e \u003ci\u003eSusan H. Fox and Anthony E. Lang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Managing the Non-Motor Symptoms of Parkinson’s Disease 91\u003cbr\u003e \u003ci\u003eWerner Poewe and Klaus Seppi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Surgery for Parkinson’s Disease 121\u003cbr\u003e \u003ci\u003eJens Volkmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Future Cell- and Gene-Based Therapies for Parkinson’s Disease 145\u003cbr\u003e \u003ci\u003eTomas Björklund, Asuka Morizane, Deniz Kirik and Patrik Brundin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Parkinson-Plus Disorders 157\u003cbr\u003e \u003ci\u003eMartin Köllensperger and Gregor K. Wenning\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Tremor Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 Essential Tremor 179\u003cbr\u003e \u003ci\u003eRodger J. Elble\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Other Tremor Disorders 193\u003cbr\u003e \u003ci\u003eGünther Deuschl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Dystonia, Cramps, and Spasms\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Pathophysiology of Dystonia 205\u003cbr\u003e \u003ci\u003eMark Hallett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 General Management Approach to Dystonia 217\u003cbr\u003e \u003ci\u003eCynthia L. Comella\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Botulinum Toxin for Treatment of Dystonia 227\u003cbr\u003e \u003ci\u003eDirk Dressler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Surgical Treatments of Dystonia 241\u003cbr\u003e \u003ci\u003eChristopher Kenney and Joseph Jankovic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Wilson’s Disease 251\u003cbr\u003e \u003ci\u003eGeorge J. Brewer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Cramps and Spasms 263\u003cbr\u003e \u003ci\u003eChristine D. Esper, Pratibha G. Aia, Leslie J. Cloud and Stewart A. Factor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Stiff Person Syndrome 283\u003cbr\u003e \u003ci\u003ePhilip D. Thompson and Hans-Michael Meinck\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Chorea, Tics and other Movement Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19 Huntington’s Disease 295\u003cbr\u003e \u003ci\u003eKevin M. Biglan and Ira Shoulson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Chorea 317\u003cbr\u003e \u003ci\u003eFrancisco Cardoso\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Treatment of Tics and Tourette Syndrome 331\u003cbr\u003e \u003ci\u003eHarvey S. Singer and Erika L.F. Hedderick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Therapeutics of Paroxysmal Dyskinesias 345\u003cbr\u003e \u003ci\u003eShyamal H. Mehta and Kapil D. Sethi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Treatment of Miscellaneous Disorders 353\u003cbr\u003e \u003ci\u003eMarie Vidailhet, Emmanuel Roze and David Grabli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Myoclonus 363\u003cbr\u003e \u003ci\u003eShu-Ching Hu, Steven J. Frucht and Hiroshi Shibasaki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V Drug-induced Movement Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e25 Neuroleptic-Induced Movement Disorders 373\u003cbr\u003e \u003ci\u003eS. Elizabeth Zauber and Christopher G. Goetz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Other Drug-Induced Dyskinesias 389\u003cbr\u003e \u003ci\u003eOscar S. Gershanik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VI Ataxia and Disorders of Gait and Balance\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 Ataxia 407\u003cbr\u003e \u003ci\u003eThomas Klockgether\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Treatment of Gait and Balance Disorders 417\u003cbr\u003e \u003ci\u003eBastiaan R. Bloem, Alexander C. Geurts, S. Hassin-Baer and Nir Giladi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VII Restless Legs Syndrome\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e29 The Restless Legs Syndrome 447\u003cbr\u003e \u003ci\u003eRichard P. Allen and Birgit H€ogl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VIII Pediatric Movement Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e30 Pediatric Movement Disorders 471\u003cbr\u003e \u003ci\u003eJonathan W. Mink\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IX Psychogenic Movement Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e31 Psychogenic Movement Disorders 479\u003cbr\u003e \u003ci\u003eElizabeth Peckham and Mark Hallett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 489\u003c\/p\u003e \"This book can be strongly recommended and is an asset to libraries of both movement disorder specialists and general neurologists. Its logical structure, linking therapy with underlying pathophysiology, means that it will remain a useful reference even as new therapies inevitably emerge.\" (\u003ci\u003eThe Lancet Neurology\u003c\/i\u003e, July 2009)  \u003cp\u003e\u003cstrong\u003eMark Hallett, MD\u003c\/strong\u003e, Senior Investigator at National Institute of Neurological Disorders and Stroke (NINDS), Chief of the Medical Neurology Branch and Chief of Human Motor Control Section; Editor-in-Chief of \u003cem\u003eClinical Neurophysiology\u003c\/em\u003e; Associate Editor of \u003cem\u003eBrain\u003c\/em\u003e. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWerner Poewe,\u003c\/strong\u003e Chairman of the Department of Neurology at Medical University of Innsbruck; Editorial board member of \u003cem\u003eMovement Disorder\u003c\/em\u003e, \u003cem\u003eJournal of Neurology\u003c\/em\u003e, \u003cem\u003eJournal of Neural Transmission\u003c\/em\u003e, and \u003cem\u003eAktuelle Neurologie\u003c\/em\u003e.   Over the past few decades, neurology has seen spectacular developments in diagnostic techniques, particularly in neuroimaging and molecular genetics, accompanied by an increasing number of effective therapies to treat neurological disease. This is particularly true for the field of movement disorders. Since the highly successful introduction of levodopa about 40 years ago, the therapeutic options for Parkinson's disease have grown exponentially, often making treatment decisions difficult.  \u003c\/p\u003e\u003cp\u003eThis is the only current book on movement disorders to emphasize treatment. The authors, experts in their field, have used evidence from randomized controlled clinical trials to develop practical recommendations for every day clinical practice, bringing their personal clinical acumen and therapeutic wisdom to the book.\u003c\/p\u003e \u003cul type=\"disc\"\u003e \u003cli\u003eProvides a comprehensive update on therapies for Parkinson's disease and other movement disorders\u003c\/li\u003e \u003cli\u003eDescribes the basic mechanisms of neurodegeneration, pharmacologic interventions for motor and non-motor symptoms, and surgical management\u003c\/li\u003e \u003cli\u003eFeatures summary tables and algorithms that serve as a quick reference guide for practical treatment decisions\u003c\/li\u003e \u003cli\u003eThe expert guidance of recognised authorities will enable readers of this book to plan their patients' care with greater confidence\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003eTherapeutics of Parkinson's Disease \u0026amp; Other Movement Disorders\u003c\/i\u003e is essential reading for residents in clinical neurology, clinical research fellows in neurology and related disciplines, general neurologists, and movement disorder specialists, as well as those working in the pharmaceutical industry with an interest in movement disorders.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47990382297317,"sku":"NP9780470066485","price":223.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470066485.jpg?v=1761787600","url":"https:\/\/k12savings.com\/es\/products\/therapeutics-of-parkinsons-disease-and-other-movement-disorders-isbn-9780470066485","provider":"K12savings","version":"1.0","type":"link"}